Ambresin Aude, Mantel Irmela
Unité de rétine médicale, Hôpital ophtalmique universitaire Jules Gonin, Av. de France 15, Lausanne.
Rev Med Suisse. 2007 Jan 17;3(94):137-41.
Age related macular degeneration (AMD) is an ocular disease with high prevalence among elderly persons. Two different forms exist: dry AMD, usually slowly progressive, and neovascular AMD (wet form) more aggressive. Photodynamic therapy is used to treat the wet form and anti VEGF treatments recently became available and offer a real change in the prognostic of wet AMD. Two products are registered and used in Switzerland (Macugen and Lucentis), a third "off labels product", Avastin is also currently used in clinical practice. Nevertheless, both the duration of treatment and the number of injection requested to stabilise the disease were not defined in the studies. Ongoing studies are mainly evaluating combined treatments and long acting form of the drug.
年龄相关性黄斑变性（AMD）是一种在老年人中患病率很高的眼部疾病。它有两种不同的形式：干性AMD，通常进展缓慢；以及新生血管性AMD（湿性形式），更为侵袭性。光动力疗法用于治疗湿性形式，抗VEGF治疗最近已可用，并为湿性AMD的预后带来了真正的改变。有两种产品在瑞士注册并使用（Macugen和Lucentis），第三种“未注册产品”阿瓦斯汀目前也在临床实践中使用。然而，研究中并未明确治疗的持续时间以及稳定病情所需的注射次数。正在进行的研究主要评估联合治疗和药物的长效形式。
